News coverage about Five Prime Therapeutics (NASDAQ:FPRX) has trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.4380295108165 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Noteworthy Friday Option Activity: FPRX, LULU, GOOGL (nasdaq.com)
- Five Prime Adds Former CytomX-Genentech Immuno-Onco Vet To The Roster (biospace.com)
- Is a Near-Term Bearish Trend Developing for Five Prime Therapeutics Inc (FPRX)? – Sparta Review (spartareview.com)
- Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research – GlobeNewswire (press release) (globenewswire.com)
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded down 1.54% during midday trading on Friday, reaching $28.06. The company’s stock had a trading volume of 333,976 shares. Five Prime Therapeutics has a 1-year low of $25.97 and a 1-year high of $60.98. The stock has a 50 day moving average of $29.00 and a 200-day moving average of $34.18. The company’s market capitalization is $785.26 million.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.15) by $0.43. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The firm had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. During the same quarter last year, the company posted ($0.49) EPS. Five Prime Therapeutics’s revenue for the quarter was down 16.1% on a year-over-year basis. On average, equities research analysts anticipate that Five Prime Therapeutics will post ($5.16) earnings per share for the current year.
A number of equities analysts recently issued reports on the company. Jefferies Group LLC reissued a “buy” rating and set a $55.00 price target on shares of Five Prime Therapeutics in a report on Monday, May 15th. BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Wednesday, April 26th. Finally, ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $60.80.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Five Prime Therapeutics (NASDAQ:FPRX) Stock Price” was originally published by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://rinconhillneighbors.org/2017/08/19/five-prime-therapeutics-nasdaqfprx-given-news-sentiment-score-of-0-10-updated-updated.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with our FREE daily email newsletter.